With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy—proton beam therapy or intensity modulated radiation therapy (IMRT)—achieved ...

For patients with intermediate- or low-risk localized prostate cancer, intensity-modulated radiation therapy (IMRT) and proton beam therapy are both safe and effective options, according to results of ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects. Patients with prostate cancer who receive ...

prostate cancer patient pelvic lymph node treatment Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a ...

Over a median follow-up period of more than five years, patients were asked to complete repeated questionnaires logging bowel, urinary and sexual function after receiving one of the two radiation ...

In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...

Mack Roach, III, MD, FASTRO, has been chosen by the American Society for Radiation Oncology (ASTRO) to receive its 2024 Gold Medal Award. Roach is being recognized with ASTRO’s highest honor for his ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...